Impact Biomedical (IBO) Other Operating Expenses (2022 - 2026)
Impact Biomedical's (IBO) quarterly Other Operating Expenses came in at $675000.0 in Q1 2026, down 9.15% YoY from $743000.0 in Q1 2025, and down 3.98% on a QoQ basis from $703000.0 in Q3 2025.
Impact Biomedical (IBO) Other Operating Expenses (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Other Operating Expenses data on file, last reported at $675000.0 in Q1 2026.
- Quarterly Other Operating Expenses fell 9.15% year-over-year to $675000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 91.89% YoY) and the FY2024 annual result came in at $28.1 million, up 711.72% from the prior year.
- Other Operating Expenses slipped to $675000.0 in Q1 2026, from $703000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $26.5 million in Q4 2024 to a low of $440000.0 in Q1 2024.
- A 5-year average of $2.4 million and a median of $675000.0 in 2026 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 1314.46% in 2024, down 50.9% in 2024.
- Tracing IBO's Other Operating Expenses over 5 years: stood at $443000.0 in 2022, then jumped by 323.02% to $1.9 million in 2023, then jumped by 1314.46% to $26.5 million in 2024, then sank by 97.35% to $703000.0 in 2025, then fell by 3.98% to $675000.0 in 2026.
- The last three Other Operating Expenses figures came in at $675000.0 (Q1 2026), $703000.0 (Q3 2025), and $913000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 462,000.00 |
| Mar 31, 2026 | 675,000.00 |
| Sep 30, 2025 | 703,000.00 |
| Jun 30, 2025 | 913,000.00 |
| Mar 31, 2025 | 743,000.00 |
| Dec 31, 2024 | 26.51 Mn |
| Sep 30, 2024 | 534,000.00 |
| Jun 30, 2024 | 463,000.00 |
| Mar 31, 2024 | 440,000.00 |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 937,000.00 |
| Jun 30, 2023 | 943,000.00 |
| Mar 31, 2023 | 505,000.00 |
| Dec 31, 2022 | 443,000.00 |
| Sep 30, 2022 | 462,000.00 |
| Jun 30, 2022 | 507,000.00 |